Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2648-2658

  Toriola, Adetunji T ^a,b   Cheng, Ting Yuan D ^c   Neuhouser, Marian L ^c   Wener, Mark H ^d   Zheng, Yingye ^c   Brown, Elissa ^c   Miller, Joshua W ^e   Song, Xiaoling ^c   Beresford, Shirley A A ^c   Gunter, Marc J ^f   Caudill, Marie A ^g   Ulrich, Cornelia M ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g Department of Molecular Biology and Genetics   (United States)

Author keywords

C reactive protein (CRP); colorectal cancer; early detection; serum amyloid A (SAA); women

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; SERUM AMYLOID A;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RECTUM CANCER; RISK ASSESSMENT;

AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84875590352     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27942     Document Type: Article

References (37)

1. Ulrich CM, Bigler J, Potter JD,. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-40.
2. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7.
3. Ullman TA, Itzkowitz SH,. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-16.
4. Canavan C, Abrams KR, Mayberry J,. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharm Ther 2006; 23: 1097-104.
5. Flossmann E, Rothwell PM,. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13.
6. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-66.
7. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
8. Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011; 106: 1340-50.
9. Gabay C, Kushner I,. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
10. MacGregor AJ, Gallimore JR, Spector TD, et al. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004; 50: 130-4.
11. Maury CP,. Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci (Lond) 1985; 68: 233-8.
12. Raynes JG, Cooper EH,. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol 1983; 36: 798-803.
13. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009; 27: 3437-44.
14. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. J Am Med Assoc 2004; 291: 585-90.
15. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-8.
16. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483-7.
17. Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 690-5.
18. Prizment AE, Anderson KE, Visvanathan K, et al. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2011; 20: 297-307.
19. Zhang SM, Buring JE, Lee IM, et al. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142: 425-32.
20. Ito Y, Suzuki K, Tamakoshi K, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol 2005; 15: S185-9.
21. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24: 5216-22.
22. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20: 15-26.
23. Allin KH, Bojesen SE, Nordestgaard BG,. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217-24.
24. Chan AT, Ogino S, Giovannucci EL, et al. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011; 140: 799-808, quiz e11.
25. Tsilidis KK, Branchini C, Guallar E, et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008; 123: 1133-40.
26. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010; 172: 407-18.
27. Toriola AT, Ulrich CM,. Is there a potential use for C-reactive protein as a diagnostic and prognostic marker for colorectal cancer? Future Oncol 2011; 7: 1125-8.
28. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.
29. Centers for Disease Control and Prevention. Colorectal cancer screening rates: prevention and early detection: keys to reducing deaths, vol. 2011, 2011.
30. Langer RD, White E, Lewis CE, et al. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003; 13: S107-21.
31. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998; 19: 61-109.
32. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003; 13: S122-8.
33. Poole S, Walker D, Gaines Das RE, et al. The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J Immunol Methods 1998; 214: 1-10.
34. Manley PN, Ancsin JB, Kisilevsky R,. Rapid recycling of cholesterol: the joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 2006; 66: 784-92.
35. Schultz DR, Arnold PI,. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990; 20: 129-47.
36. Malle E, Sodin-Semrl S, Kovacevic A,. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009; 66: 9-26.
37. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011; 103: 1112-22.